At Alfa Cytology, we are actively seeking collaborative partnerships to license our cutting-edge OncoBact™ oncolytic bacteria platform or to co-develop therapeutic candidates utilizing this innovative technology. Our OncoBact™ platform represents a significant advancement in cancer treatment, offering a unique combination of precision targeting and versatile therapeutic potential. This platform is designed to harness the body's own immune system to fight cancer, with our bacteria engineered to specifically target tumor cells while minimizing damage to healthy tissue.

If you are interested in any of the projects, please contact us for further discussion. We eagerly anticipate the opportunity to collaborate with you.

By engaging with our OncoBact™ platform, partners gain access to a comprehensive suite of tools and expertise dedicated to advancing the development of novel oncolytic bacterial therapies. We are committed to leveraging the unique properties of our platform to create therapies with exceptional efficacy and safety profiles, accelerating the discovery and development of groundbreaking cancer treatments.

Whether you are interested in licensing our platform for your proprietary drug development programs or wish to collaborate on co-development initiatives, Alfa Cytology offers flexible partnership models tailored to your specific needs. Join us in our mission to transform cancer treatment through innovative science and collaborative innovation.